Clinical trial
Cerebellar-Targeted Repetitive Transcranial Magnetic Stimulation (rTMS) for Autism Spectrum Disorder: A Novel Treatment Approach
NCT07910305 is registered in ClinicalTrials.gov with Sir Run Run Shaw Hospital as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started November 2026. Interventional study, 120 participants (estimated). Lead sponsor Sir Run Run Shaw Hospital; China. Primary measure: Change in Social Responsiveness Scale (SRS) Total Score From Baseline to Week 2.
How it compares
1,092 similar trials: same condition (Autism Spectrum Disorder) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- Cerebellar-Targeted Repetitive Transcranial Magnetic Stimulation (rTMS) for Autism Spectrum Disorder: A Novel Treatment Approach
- Lead sponsor
- Sir Run Run Shaw Hospital
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- November 1, 2026
- Completion date
- December 31, 2028
- Enrollment
- 120 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Registry terms: tms
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 6 Years
- Maximum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 1
- Countries
- China
- Lead sponsor
- Sir Run Run Shaw Hospital
Arms
As registered; 1 arm.
| Arm | Type | Interventions |
|---|---|---|
| Individualized Cerebellar-Targeted rTMS | Experimental | Individualized Cerebellar-Targeted Repetitive Transcranial Magnetic Stimulation |
Show registry wordingParticipants in this arm will receive individualized cerebellar-targeted repetitive transcranial magnetic stimulation (rTMS) guided by MRI-based neuronavigation. The stimulation will be delivered using an intermittent theta-burst stimulation (iTBS) protocol at 90% of the resting motor threshold (RMT). Each treatment day will consist of two stimulation sessions separated by a 15-minute rest interval, delivering a total of 1,200 pulses per day. Treatment will be administered five days per week for two consecutive weeks, resulting in a total of 10 treatment days. Clinical assessments and MRI examinations will be performed at baseline, week 2, and week 12 to evaluate treatment-related changes in ASD symptoms and brain function. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Change in Social Responsiveness Scale (SRS) Total Score From Baseline to Week 2 | Baseline and Week 2 |
Show registry wordingThe Social Responsiveness Scale (SRS) is a caregiver-reported questionnaire used to assess social communication and interaction difficulties in individuals with autism spectrum disorder. The scale consists of 65 items, each rated from 0 to 3, with a total score ranging from 0 to 195. Higher scores indicate greater severity of social impairment. The primary outcome is the change in SRS total score from baseline to week 2 following individualized cerebellar-targeted repetitive transcranial magnetic stimulation (rTMS). | |
Lead sponsor's other trials
Sir Run Run Shaw Hospital, most recent start first.
+129 more trials See the organization page
Similar trials
Same condition (Autism Spectrum Disorder) and phase, most recent start first.
+1,087 more trials See the condition page